Semaglutide: GLP-1 Receptor Agonist Research Guide

Semaglutide is a long-acting, acylated GLP-1 (glucagon-like peptide-1) receptor agonist. It is a synthetic analogue of the human GLP-1 hormone, sharing approximately 94% sequence homology with the native peptide. The acylation at position 26 via a C18 fatty diacid chain provides an extended half-life of approximately 7 days, enabling once-weekly administration in clinical settings.

As a research compound, Semaglutide is one of the most extensively studied GLP-1 receptor agonists, with a substantial body of clinical trial data from Novo Nordisk's SUSTAIN (type 2 diabetes) and STEP (obesity) programmes. It is studied in the context of metabolic regulation, appetite modulation, and cardiovascular risk factors.

Semaglutide exerts its effects primarily through agonism of the GLP-1 receptor, which is expressed in the pancreas, brain, heart, and gastrointestinal tract:

• Pancreatic effects — stimulates glucose-dependent insulin secretion from beta cells and suppresses glucagon release from alpha cells, reducing hepatic glucose output
• Central appetite regulation — activates GLP-1 receptors in the hypothalamus and brainstem, reducing energy intake through enhanced satiety signalling and delayed gastric emptying
• Cardiovascular effects — research has demonstrated cardioprotective signals including reductions in blood pressure, inflammation markers, and atherosclerotic plaque formation in preclinical models

Unlike short-acting GLP-1 agonists, Semaglutide's extended half-life provides continuous receptor engagement, which research suggests produces more sustained effects on appetite and body weight regulation than pulsatile dosing.

Semaglutide has undergone extensive clinical evaluation across two major programmes:

SUSTAIN programme (cardiovascular and glycaemic outcomes): SUSTAIN-6 demonstrated a 26% reduction in major adverse cardiovascular events (MACE) versus placebo in high-risk patients. Subsequent trials confirmed consistent HbA1c reductions of 1.5–1.8% alongside weight loss of 4–6kg over 30 weeks.

STEP programme (obesity research): The STEP 1 trial (NEJM, 2021) evaluated 2.4mg/week semaglutide in adults with obesity, reporting mean body weight reduction of 14.9% over 68 weeks. STEP 3 combined semaglutide with intensive behavioural intervention and observed reductions of up to 16%. STEP 4 demonstrated weight regain upon discontinuation, supporting research into sustained treatment models.

Semaglutide remains an active area of research in areas including non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and addiction neuroscience as of 2026.

RetaLABS Semaglutide is supplied as a lyophilised (freeze-dried) powder. Standard research reconstitution protocol:

• Use bacteriostatic water (not sterile water) to extend reconstituted solution stability
• Inject water slowly along the vial wall — do not aim directly at the lyophilised cake
• Gently swirl until fully dissolved — do not vortex or shake vigorously
• Typical research concentration: 1–2mg/mL depending on protocol
• Store lyophilised vials at −20°C (or 2–8°C short-term), protected from light
• Reconstituted solution: refrigerate at 2–8°C, use within 4–6 weeks
• Do not freeze reconstituted solution

RetaLABS Semaglutide is sourced from manufacturers who supply a Certificate of Analysis (COA) with each batch. A COA documents the compound identity, testing methodology, and lot-specific results — the primary quality document for research peptide procurement. COAs are available on request via [email protected].

For guidance on how to read and evaluate a research peptide COA, what testing methods to look for, and how to assess supplier transparency, see our Research Peptides Sourcing Guide. All products are supplied for laboratory and research purposes only — not for human consumption.